financial analysis of pfizer inc

25
Team: Apostol Andreea Gheorghe Diana Rosca Nicoleta

Upload: andreea-apostol

Post on 13-Apr-2015

60 views

Category:

Documents


0 download

DESCRIPTION

Financial Analysis of Pfizer Inc

TRANSCRIPT

Page 1: Financial Analysis of Pfizer Inc

Team: Apostol AndreeaGheorghe Diana

Rosca Nicoleta

Page 2: Financial Analysis of Pfizer Inc

Pfizer is the world's largest research-based biomedical and pharmaceutical company. The corporate headquarter is located in New York, with major research and development locations in the United States and England. In 2007, Pfizer earned $48.4 billion in revenues and invested $8.1 billion in research and development.

Pfizer Inc, founded in 1849, is dedicated to better health and greater access to health care for people and their valued animals. Every day, approximately 85,000 colleagues in more than 150 countries work to discover, develop, manufacture and deliver quality, safe and effective prescription medicines to patients.

Page 3: Financial Analysis of Pfizer Inc

Short-term liquidity ratios:

• Current ratio• Quick ratio• Cash ratio

• Average collection period

• Average payment period

• Inventory turnover

Long term solvency ratios:

• Debt ratio• Debt to equity ratio

• Debt to tangible net worth

• Long-term debt to equity ratio

• Interest coverage ratio

Page 4: Financial Analysis of Pfizer Inc

Profitability ratios:• ROE• ROI

• Gross profit rate• Return on sales• Asset turnover

• ROA• Sales per employee

Market price and dividend ratio

• EPS• PER

• Market to book ratio

• Dividend yield ratio• Dividend payout

ratio

Page 5: Financial Analysis of Pfizer Inc

FINANCIAL RATIOS 2007 2006 2005

I. Short-Term Liquidity Ratios      

1. Current ratio 2.14 2.19 1.47

2. Quick ratio 1.64 1.75 1.14

3. Cash ratio 1.19 1.31 0.79

4. Average Collection Period 72.50 72.27 68.06

5. Average Payment period 76.25 82.16 42.71

6. Inventory Turnover 0.48 0.31 0.33

II. Long Term Solvency Ratios      

1. Debt ratio 0.085 0.081 0.083

2. Debt to Equity Ratio 0.2 0.11 0.27

3. Debt to Tangible Net Worth 0.29 0.16 0.47

4. Long-Term Debt to Equity Ratio 0.11 0.77 0.10

5. Interest coverage ratio 17.08 23.45 23.34

III. Profitability Ratios      

1. Return on Shareholders' Equity (ROE) 0.029 0.070 0.030

2. Return on Investment (ROI) 0.110 0.250 0.111

3. Gross Profit Rate 76.80% 84.20% 83.40%

4. Return on Sales 0.168 0.399 0.157

5. Asset Turnover 0.210024 0.210607 0.10658

6. Return on Assets (ROA) 0.017 0.041 0.01670

7. Sales per Employee      

IV. Market Price and Dividend Ratios      

1. Earnings per Share(EPS) 0.290 0.660 0.540

2. Price/Earnings Ratio (PER) 78.08 38.80 42.70

3. Market to Book Ratio 2.38 2.58 2.63

4. Dividend yield ratio 348.25 267.14 236.88

5. Dividend payout ratio 27193.7 10365.8 10115.1

Page 6: Financial Analysis of Pfizer Inc

For Pfizer the current ratio did not suffer a significant change in year 2007, unlike year 2006 when it increased with more than 25% (from 1.47 to 2.19).

However, the value of the rate has changed because of a decrease in the current assets and an increase in the current liabilities.

The ratio 2.14 to 1 is a good one because this means that the company is able to cover all the current liabilities with the current assets.

Page 7: Financial Analysis of Pfizer Inc

This ratio also suffers a diminish, but not a relevant one, from 1.75 in 2006 to 1.64 in 2007. This change is due to a small variation of the ratio cash + accounts receivables to current liabilities. Therefore, the company is able to pay its current liabilities from its most liquid assets because the value of the ratio is still above 1.

Page 8: Financial Analysis of Pfizer Inc

The quick ratio decreased with 9,16% because the quantity of cash is smaller than the one in year 2006 and also the current liabilities rose.

This modifications show the fact that the company is oriented to invest more, this is why the liquidity has diminished, and also to enlarge its activity, this is why the debts, the short one, doubled.

Page 9: Financial Analysis of Pfizer Inc

This ratio oscillated a lot during the last 3 years: in 2006 it experienced a 2 fold increase (from 42 to 82) but in 2007 it did not keep the same trend, slowing down with almost 10%.

The fact that the period to pay the company’s debts declined is not very favorable, because the company has less time to pay the accounts payable.

However the situation is not a grey one because the payment period is lower then the collection period. This shows that the firm first convert its receivables in cash and then it pay its suppliers.

Page 10: Financial Analysis of Pfizer Inc

In 2007 the average collection period continue to grow but more insignificant then in year 2006, below 1%. This shows that the period in which the receivables become cash increased. The period is not a big one, the average payment of its clients is almost 2 and a half months, which is a common practice in every industry.

Page 11: Financial Analysis of Pfizer Inc

The inventory turnover grew with 54%. This represents a significant increase and it was possible because of the growth of the cost of sales with almost 50%

Page 12: Financial Analysis of Pfizer Inc

The ratio increased because of the growth of the company’s debts and the descrease of the owner’s equity. This shows that the company has more debts to financial entities then to investors, also the lower quantity of owner’s equity shows a withdrawl.

Page 13: Financial Analysis of Pfizer Inc

The value of this ratio is 0.43, bigger then the one from year 2006 because the company’s debts increased. Despite of the debt’s growth the company is not highly leverages and it is able to pay its debts. This situation is a positive one for the investors.

Page 14: Financial Analysis of Pfizer Inc

The value of this ratio is 0,11, it increased but is not a negative step because it is lower which is a favorable situation. It shows the fact that the company is able to pay its long term liabilities from the equity of the shareholders. So the degree of financial leverage is not a big one.

Page 15: Financial Analysis of Pfizer Inc

It decreased compared to the base year, returning to the value recorded two yesrs before, in 2005. This is due to a drop in net income, that is also similar to the recorded value of 2005.

Page 16: Financial Analysis of Pfizer Inc

As it was expected the Return On Sales is also lower than the in 2006. In fact it is closer to the value recoreded in 2005. Again this is caused by the lower Net Income recoreded in 2007.

Page 17: Financial Analysis of Pfizer Inc

Compared to the base year the ROI suffers too from a decrease and again we notice a resemblance with the values recorded in 2005. This happend form the same reason, the low net income in 2007.

Page 18: Financial Analysis of Pfizer Inc

As it is already known, the low Net Income of 2007 is influencing most of the profitability ratios, including the Return on Assets, causing it to present a value very close to the one of 2005.

Page 19: Financial Analysis of Pfizer Inc

The single indicator of this group to show a steady evolution, however sill slightly lower than the base year, this was to be expected since both sales and assets are very close to the what was recoreded in 2006.

Page 20: Financial Analysis of Pfizer Inc

A decreasing Gross Profit to Net Sales ratio is a negative sign, indicating the company is becoming less profitable. The company may even have an increasing Net Sales, but the cost to the company to generate those extra sales may be degrading profits.

However it is not the case here as the Net Income was considerably lower in 2007 compared to the base year. This ratio varies wildly between companies and industries, so the best knowledge from this ratio can be gained by measuring it over several periods. The recoreded value is significantly lower than any of the two previous years. This major decrease is explained by the negative evolution of the Gross Profit - cost of goods sold, being almost 50% higher.

Page 21: Financial Analysis of Pfizer Inc
Page 22: Financial Analysis of Pfizer Inc
Page 23: Financial Analysis of Pfizer Inc

Market price 31.12.07 22.9

Market price 31.12.06 25.9

Market price 31.12.05 23.45

Page 24: Financial Analysis of Pfizer Inc
Page 25: Financial Analysis of Pfizer Inc